Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week safety and tolerability study of NVA237 vs tiotropium in Japanese COPD patients
jRCT2080221091Phase 3
- Sponsor
- Novartis
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Primary safety and tolerability endpoints.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2080221091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221091.